www.adscientiam.fr
Location: France, Ile-de-France, Paris
Employees: 11-50
Total raised: $2.31M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | Station F | stationf.c... |
| - | Startup Le... | startuplea... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.07.2017 | - | $2.31M | - |
Mentions in press and media 9
| Date | Title | Description |
| 29.06.2026 | Ad Scientiam Unveils Positive Interim 1-Year Longitudinal Results for MSCopilot® at EAN 2026 | MSCopilot® is a FDA-registered and CE-marked class IIa Software as a Medical Device (SaMD). It enables people with MS to assess key functional domains impacted by the disease: walking capacity, manual dexterity, cognitive functions, and low... |
| 15.04.2026 | Ad Scientiam launches U.S. subsidiary and expands deployment of MSCopilot® following FDA registration | Ad Scientiam announces the creation of its U.S. subsidiary, Ad Scientiam Inc., to support the deployment of MSCopilot® in the United States. The launch of Ad Scientiam Inc. in the U.S. marks a major milestone in bringing MSCopilot® to MS ce... |
| 01.09.2025 | Europe’s digital health innovators warn: “unite or fall behind” | Today, a coalition of 33 digital health organisations from across Europe, including industry associations and startups from France, Germany and other EU member states, has published a joint statement urging European decision-makers to estab... |
| 19.06.2025 | Ad Scientiam Announces Completion of Enrollment in the pivotal MS-DETECT Study | A significant milestone achieved with the completion of enrollment in MS-DETECT, one of the most ambitious digital biomarker trials conducted in MS The ability to capture early signs of progression through standardized, objective, and longi... |
| 03.06.2025 | MSCopilot® receives CE marking under the European Union Medical Device Regulation (EU MDR) 2017/745 | A major milestone for the digital monitoring of people living with multiple sclerosis PARIS, FRANCE, FRANCE, June 3, 2025 /EINPresswire.com/ -- On the occasion of World Multiple Sclerosis Day, Ad Scientiam announced that MSCopilot®, its cla... |
| 08.04.2025 | Ad Scientiam Present Promising Interim Findings on Digital Biomarkers in Myasthenia Gravis at AAN 2025 | Interim results from the ME&MGopen study demonstrate strong adherence, high usability, and meaningful clinical associations in myasthenia gravis The ME&MGopenTM study highlights the potential of digital health tools such as ME&M... |
| 26.02.2025 | Ad Scientiam Launches a Pilot Project in the U.S. to Assess MSCopilot®’s Integration into Routine Care for MS Patients | Ad Scientiam launches the MS-FLOWER project in the US to integrate MSCopilot® in routine care for multiple sclerosis, enhancing monitoring and decision-making We believe MS-Flower will highlight the tool's potential to streamline MS care, m... |
| 17.09.2024 | Ad Scientiam to Provide Digital Biomarker Expertise to Abata Therapeutics in First Treg Cell Trial for Progressive MS | Ad Scientiam to provide digital biomarker expertise to Abata Therapeutics in a first-in-human Phase I clinical study of ABA-101 in patients with progressive MS We're thrilled to work with Ad Scientiam's digital biomarkers related to the dis... |
| - | Ad Scientiam | “Instagram Facebook Youtube Wordpress We are convinced that better care for people with serious and disabling diseases requires better data. Indeed, t” |